FIVE STAGES. ONE INTEGRATED SYSTEM.

Most MedTech commercialization failures aren't random. They occur at predictable points in the journey — where assumptions go untested and critical decisions are made without the right intelligence. The ECHELON Framework™ addresses each one in sequence.

01

STAGE

Most innovators know their TAM. Few have stress-tested it against the question that determines commercial viability: Is there a code? What does it pay? Is there a coverage determination?

ECHELON begins with the reimbursement filter — the lens that separates real commercial opportunity from an addressable market that exists only on paper. Site-of-care economics (HOPD vs. ASC vs. office-based) determine whether a procedure is economically viable in the settings where it will actually be performed. That question precedes everything else.

From there, ECHELON stress-tests the full set of assumptions driving downstream decisions: competitive position, clinical adoption barriers, channel access, and stakeholder economics. Who are the real buyers, the real blockers, and the real decision-makers?

Generic TAM exercises don't answer those questions. ECHELON does.

Foundation

Validate The Market Reality

01

STAGE

02

STAGE

Most companies design their regulatory pathway first, then figure out reimbursement. The ECHELON Framework reverses the sequence.

Reimbursement strategy should drive regulatory strategy — not follow it. The reimbursement landscape determines which regulatory pathway makes the most commercial sense: what billing codes are available, what payer coverage looks like, what evidence standard CMS will require.

ECHELON designs both as a unified architecture — 510(k), PMA, or De Novo mapped against CMS strategy, coding pathways, and payer requirements simultaneously. Regulatory and reimbursement run in parallel by design, not by accident.

Aligned from the start. Not retrofitted after approval is granted.

Architecture

Design Regulatory And Reimbursement Strategy As A Unified System

03

STAGE

You get one shot at the pivotal study. Most are designed to clear the FDA bar — safety and effectiveness. That's the floor, not the ceiling.

The FDA asks: Is it safe and effective? CMS asks: Is it reasonable and necessary? Those are different questions — and a study designed only to answer the first often produces data that is irrelevant to the coverage determination.

ECHELON designs clinical studies as strategic instruments: generating the superiority data that supports new or enhanced coding, building the economic evidence that drives payer coverage determinations, and capturing the outcomes data that moves clinicians and health systems. One evidence architecture. Three audiences served simultaneously.

A study designed only for approval leaves reimbursement and adoption to chance. That is a recoverable mistake — but an expensive one.

Evidence

Design The Study That Wins Approval, Reimbursement, And Adoption.

04

STAGE

The physician who selects your device and the organization that controls patient flow are in different buildings with different economics. Most companies sell to the first and wonder why adoption stalls.

Clinical champions win trials. They don't control supply chains, VAC approvals, or the scheduling infrastructure that determines whether a procedure actually gets performed. That structural split — between the clinician who wants the device and the organization that decides whether it's available — is the most common reason adoption fails after a successful launch.

ECHELON maps the full decision architecture before launch: physicians, administrators, value analysis committees, supply chain, and payers. Each stakeholder operates with different priorities, different budget authority, and different definitions of value. The access strategy has to move through all of them.

Identifying that architecture and designing against it in advance is what separates Echelon engagements from generic commercialization advice.

Access

Map Who Actually Decides

05

STAGE

A successful launch is not a scalable business. The infrastructure required to grow beyond early adopters is different from what it took to get the first accounts — and the threats that emerge post-launch are different from the ones you planned for.

ECHELON designs the commercial model for sustained growth and builds three post-launch disciplines into the architecture from day one.

Reimbursement defense: Codes get bundled and rates get cut. The reimbursement position you launched with will not hold without active surveillance and advocacy. ECHELON builds the monitoring and response infrastructure before it's needed.

Competitive positioning: Every 510(k) pathway you opened is now open to followers. Next-generation entrants will use your clinical data, your coding infrastructure, and your established market to accelerate their own entry. Anticipating that competitive dynamic — and building against it — is a launch-day discipline, not a Year 3 problem.

Lifecycle evidence generation: Post-market data is the currency of long-term reimbursement and clinical positioning. ECHELON designs the real-world evidence strategy that sustains coverage, supports coding defense, and builds the clinical narrative that early adopters can't provide alone.

Scale

Build A Commercial Engine That Sustains

FOR INNOVATORS

MedTech Companies & Developers

"How do I clear this gate?"

Companies navigating commercialization in real time use the ECHELON Framework™ as a forward-looking roadmap — identifying what needs to be true at each stage, where the gaps are, and what decisions need to be made now to protect commercial position later.

FOR INVESTORS & STRATEGICS

VCs, PE Firms, And Strategic Acquirers

"Has this company cleared this gate — and what's the real cost to finish?"

Investors and strategics apply the same framework as a diagnostic — evaluating where a company actually stands against each stage, what's been de-risked, what remains exposed, and what it will cost to close the gap between current state and commercial readiness.

Two Lenses. One Framework.

Dual-Audience Framework

The ECHELON Framework™ is designed to serve two distinct audiences — who are asking fundamentally different questions about the same five stages

The Echelon Framework™ powers

The ECHELON Framework™ is designed to serve two distinct audiences — who are asking fundamentally different questions about the same five stages

INTELLIGENCE AT SCALE

Echelon Development Group

Human Expertise

Deep domain knowledge applied through direct engagement

ASTERIntel

ECHELON Framework™

Proprietary Methodology

The framework that structures every commercialization decision

ASTERIntel

Scalable Intelligence

AI-enabled platform that operationalizes the framework at speed

Ready to pressure-test your commercialization logic?

ECHELON Framework™ assessments are available through Echelon Development Group's advisory engagements. Let's identify where your strategy is strong — and where it isn't.